Search

everythinglearnresearchcommunity

for

Search:↓

Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.

Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.

A woman's complete hair loss condition improved after recovering from COVID-19.

Baricitinib might help treat hair loss in lupus patients, but more research is needed.

Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

Topical tofacitinib may grow hair better than minoxidil by increasing VEGF and reducing inflammation.

New alopecia treatments aim for better results and fewer side effects.

Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.

Interleukin levels are higher in alopecia areata patients but don't predict disease severity or duration.

Beard hair loss can signal early diabetes and thyroid issues, treatable with specific cream.

Frontal fibrosing alopecia shows increased inflammation and JAK-STAT pathway activity without reduced hair proteins.

Dermatologists often neglect hair disorders due to complexity and lack of clear treatments, impacting patient care and highlighting the need for better education and interest in this area.

A 6-year-old girl with alopecia universalis regrew most of her hair after treatment with simvastatin/ezetimibe, minoxidil, and prednisolone.

Baricitinib may effectively treat oral lichen planus.

Topical treatments helped a child with Down syndrome and severe hair loss regrow most of his hair.

Topical calcipotriol successfully treated hair loss in three patients with Alopecia Totalis.

Both vitiligo and alopecia areata involve an immune response triggered by stress and specific genes, with treatments targeting this pathway showing potential.

Targeted cancer therapies have a significant but lower risk of causing hair loss compared to chemotherapy.

The PRP-like cosmetic product with postbiotics effectively treats hair loss in Alopecia areata.

The drug BAY 1158061 is safe, well-tolerated, and shows potential for treating diseases related to prolactin.

The combination therapy was effective and well-tolerated, especially in young patients.

Minoxidil was more effective than laser therapy for hair loss, and the report also highlighted the need for more research on PRP for a different hair loss condition, the impact of social media on alopecia views, and a warning on turmeric causing nail discoloration.

Calcipotriol's effectiveness for treating alopecia areata is unclear and needs more research.

Baricitinib significantly regrows hair in severe alopecia areata patients.

Continuous baricitinib is needed to keep hair regrowth in severe alopecia areata.

Experts recommend personalized treatment plans for best outcomes in managing Alopecia Areata.

COVID-19 may harm male reproductive health and lower testosterone levels, potentially affecting fertility and causing erectile dysfunction. More research is needed.

Alopecia areata is an autoimmune condition causing hair loss, linked to genetic factors and immune system issues, with no cure yet.